


Form PTO-1390		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER P2025 <b>09/674526</b>
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 09/674,526
INTERNATIONAL APPLICATION NO. PCT/JP99/02681	INTERNATIONAL FILING DATE 21 May 1999	PRIORITY DATE CLAIMED 22 May 1998	
TITLE OF INVENTION DRUG COMPLEX			
APPLICANT(S) FOR DO/EO/US Hiroshi SUSAKI, Kazuhiro INOUE, and Hiroshi KUGA			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information.			
<p>1. <input type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input checked="" type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)).</p> <p>4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).</p> <p>5. <input type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p>a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</p> <p>b. <input type="checkbox"/> has been communicated by the International Bureau.</p> <p>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)).</p> <p>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</p> <p>b. <input type="checkbox"/> have been communicated by the International Bureau.</p> <p>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p>d. <input type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>"Executed"</p> <p>10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (U.S.C. 371(c)(5)).</p>			
<b>Items 11 to 16 below concern other document(s) or information included:</b>			
11. Assignee: <u>DAIICHI PHARMACEUTICAL CO., INC.</u>			
12. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.			
13. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.			
14. <input type="checkbox"/> A FIRST preliminary amendment.			
<input checked="" type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.			
15. <input type="checkbox"/> A substitute specification.			
16. <input type="checkbox"/> A change of power of attorney and/or address letter.			
17. <input checked="" type="checkbox"/> Other items or information:			
Cover Letter.			
Cover Letter Accompanying Sequence Listing and Statement that the Paper and Computer Readable are the Same.			
Copy of Form Notification of Missing Requirements.			
Diskette containing Sequence Listing, with paper copies of the same (1 page).			

U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 09/674,526		INTERNATIONAL APPLICATION PCT/JP99/02681		ATTORNEY'S DOCKET NUMBER P20257	
18. <u>    </u> The following fees are submitted:  <div style="margin-left: 40px;">           Basic National Fee (37 CFR 1.492(a)(1)-(5)):             Search report has been prepared by the EPO or JPO. .... \$ 860.00             International preliminary examination fee paid to USPTO (37 CFR 1.482). .... \$ 690.00             No international preliminary examination fee paid to USPTO (37 CFR 1.482) but            international search fee paid to USPTO(37 CFR 1.445(a)(2)). .... \$ 710.00             Neither international preliminary examination fee (37 CFR 1.482) nor            international search fee (37 CFR 1.445(a)(2) paid to USPTO. .... \$1,000.00             International preliminary examination fee paid to USPTO (37 CFR 1.482) and all            claims satisfied provisions of PCT Article 33(2)-(4). .... \$ 100.00   <div style="text-align: right;">ENTER APPROPRIATE BASIC FEE AMOUNT =</div> </div>				CALCULATIONS      PTO USE ONLY	
				\$ 0.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <u>    </u> 20 <u>X</u> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$ 0.00	
Claims	Number Filed	Number Extra	RATE		
Total Claims	22            - 20 =	22	X \$18.00	\$ 0.00	
Independent Claims	4                - 3 =	4	X \$80.00	\$ 0.00	
Multiple dependent claim(s) (if applicable)			+ \$270.00	\$ 0.00	
TOTAL OF ABOVE CALCULATIONS =				\$ 0.00	
<u>    </u> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$ 0.00	
SUBTOTAL =				\$ 0.00	
Processing fee of \$130.00 for furnishing the English translation later than <u>    </u> 20 <u>    </u> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$ 0.00	
Extension of Time fee in the amount of \$110.00				\$ 0.00	
TOTAL NATIONAL FEE =				\$ 0.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$ 0.00	
TOTAL FEES ENCLOSED =				\$ 0.00	
				Amount to be refunded	\$
				Charged	\$
a. <u>N/A</u> A check in the amount of \$ <u>    </u> to cover the above fees is enclosed. b. <u>    </u> Please charge my Deposit Account No. <u>        </u> in the amount of \$ <u>        </u> to cover the above fees. c. <u>X</u> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>19-0089</u> .  NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.  <div style="display: flex; justify-content: space-between;"> <div style="width: 60%;">           SEND ALL CORRESPONDENCE TO CUSTOMER NO. 7055            AT THE PRESENT ADDRESS OF:            Bruce H. Bernstein            GREENBLUM &amp; BERNSTEIN, P.L.C.            1941 Roland Clarke Place            Reston, VA 20191            (703) 716-1191         </div> <div style="width: 35%; text-align: right;">             SIGNATURE            Arnold Turk            NAME   <u>33,094</u>            REGISTRATION NUMBER         </div> </div>					

09/674526

P21257.P13

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Hiroshi SUSAKI et al.

Serial No : 09/674,526  
(National Stage of PCT/JP99/02681)

I.A. Filed : May 21, 1999

For : DRUG COMPLEX

**COVER LETTER**

Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Sir:

In order to comply with the requirements (copy enclosed) for the submission of paper and computer readable forms of amino acid sequence listing of the International Application set forth in the Notification mailed December 5, 2001 which sets a two month period of response until February 5, 2002, Applicants hereby submit:

- Transmittal Letter to the United States Designated/Elected Office Concerning a Filing Under 35 U.S.C. 371;

- Cover Letter Accompanying Sequence Listing and Statement that the Paper and Computer Readable are the Same (enclosed: a diskette containing Sequence Listing and paper copy of the same (1 page)).


And also enclosed is:

- a Preliminary Amendment; and
- an Information Disclosure Statement, form PTO-1449, and references cited.

The Commissioner is hereby authorized to charge any additional fees or credit any overpayment to Deposit Account No. 19-0089.

Should the Examiner have any questions, he is invited to contact the undersigned at the below listed number.

Respectfully submitted,  
Hiroshi SUSAKI et al.

A handwritten signature in black ink, appearing to read 'Arnold Turk', is written over a horizontal line.

Arnold Turk  
Reg. No. 33,094

January 23, 2002  
GREENBLUM & BERNSTEIN, P.L.C.  
1941 Roland Clarke  
Reston, VA 20191  
(703) 716-1191



## UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Non-PCT  
United States Patent and Trademark Office  
Washington, D.C. 20231  
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/674,526	Hiroshi Susaki	P20257

INTERNATIONAL APPLICATION NO.
PCT/JP99/02681

7055  
GREENBLUM & BERNSTEIN, P.L.C.  
1941 ROLAND CLARKE PLACE  
RESTON, VA 20191

I.A. FILING DATE	PRIORITY DATE
05/21/1999	05/22/1998

CONFIRMATION NO. 3623  
371 FORMALITIES LETTER



\*OC000000007139683\*

Date Mailed: 12/05/2001

### NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Priority Document
- Claims
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Drawings
- Initial Application Filing Fees
- Oath or Declaration
- Oath or Declaration
- Original Specification
- Preliminary Amendments
- Request for Immediate Examination

RECEIVED

DEC 13 2001

GREENBLUM & BERNSTEIN, P.L.C.

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
  - This application does not contain a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
  - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
  - APPLICANT MUST PROVIDE:

- An initial or substitute computer readable form (CRF) of the "Sequence Listing."
  - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
    - For Rules Interpretation, call (703) 308-4216
    - To Purchase PatentIn Software, call (703) 306-2600
    - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

**ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.**

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

WINSTON M ALVARADO

Telephone: (703) 305-6421

**PART 1 - ATTORNEY/APPLICANT COPY**

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
09/674,526	PCT/JP99/02681	P20257